STI571

Manufactured by Novartis. Currently (1 Nov 2000) being trialled in UK led by Newcastle.

Mechanism

Inhibits Bcr-Abl tyrosine kinase by binding to ATP binding site. Bcr-Abl is the chimeric tyrosine kinase formed from the fusion of abl on chromosome 9 to the bcr gene on chromosome 22 t(9;22).